Limits...
Increased Circulating Level of the Survival Factor GP88 (Progranulin) in the Serum of Breast Cancer Patients When Compared to Healthy Subjects.

Tkaczuk KR, Yue B, Zhan M, Tait N, Yarlagadda L, Dai H, Serrero G - Breast Cancer (Auckl) (2011)

Bottom Line: Serum GP88 level was 28.7 + 5.8 ng/ml in HV and increased to 40.7 + 16.0 ng/ml (P = 0.007) for stage 1-3 and 45.3 + 23.3 ng/ml (P = 0.0007) for stage 4 BC patients.There was no correlation between the GP88 level and BC characteristics such as age, race, tumor grade, ER, PR and HER-2 expression.These data suggest that serial testing of serum GP88 levels may have value as a circulating biomarker for detection, monitoring and follow up of BC.

View Article: PubMed Central - PubMed

Affiliation: University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD, USA.

ABSTRACT

Introduction: GP88 (PC-Cell Derived Growth Factor, progranulin) is a glycoprotein overexpressed in breast tumors and involved in their proliferation and survival. Since GP88 is secreted, an exploratory study was established to compare serum GP88 level between breast cancer patients (BC) and healthy volunteers (HV).

Methods: An IRB approved prospective study enrolled 189 stage 1-4 BC patients and 18 HV. GP88 serum concentration was determined by immunoassay.

Results: Serum GP88 level was 28.7 + 5.8 ng/ml in HV and increased to 40.7 + 16.0 ng/ml (P = 0.007) for stage 1-3 and 45.3 + 23.3 ng/ml (P = 0.0007) for stage 4 BC patients. There was no correlation between the GP88 level and BC characteristics such as age, race, tumor grade, ER, PR and HER-2 expression.

Conclusion: These data suggest that serial testing of serum GP88 levels may have value as a circulating biomarker for detection, monitoring and follow up of BC.

No MeSH data available.


Related in: MedlinePlus

Comparison of the GP88 level in healthy volunteers (HV) and breast cancer patients separated by stages (Stage 1–3) and stage 4. GP88 serum levels in healthy volunteers and breast cancer patients stage 1–3 and stage 4 were represented by box and whisker plots. The mean is represented by a + sign. The median is represented by the line inside the box. The bottom and top of the box represent the 25th and 75th percentiles. The vertical line extends to the minimum and maximum data values.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3140268&req=5

f1-bcbcr-5-2011-155: Comparison of the GP88 level in healthy volunteers (HV) and breast cancer patients separated by stages (Stage 1–3) and stage 4. GP88 serum levels in healthy volunteers and breast cancer patients stage 1–3 and stage 4 were represented by box and whisker plots. The mean is represented by a + sign. The median is represented by the line inside the box. The bottom and top of the box represent the 25th and 75th percentiles. The vertical line extends to the minimum and maximum data values.

Mentions: Statistical analysis of the results in Table 2 indicated that serum GP88 values were significantly elevated in both early stage (P = 0.007) and stage 4 patients (P = 0.0007) when compared to the GP88 serum level of healthy subjects. In addition, as shown in Figure 1, the range of GP88 values was much larger in BC patients than in healthy individuals reaching 100 ng/ml for stage 1–3 patients and 158 ng/ml in stage 4 patients when compared HV where the highest values was 39 ng/ml.


Increased Circulating Level of the Survival Factor GP88 (Progranulin) in the Serum of Breast Cancer Patients When Compared to Healthy Subjects.

Tkaczuk KR, Yue B, Zhan M, Tait N, Yarlagadda L, Dai H, Serrero G - Breast Cancer (Auckl) (2011)

Comparison of the GP88 level in healthy volunteers (HV) and breast cancer patients separated by stages (Stage 1–3) and stage 4. GP88 serum levels in healthy volunteers and breast cancer patients stage 1–3 and stage 4 were represented by box and whisker plots. The mean is represented by a + sign. The median is represented by the line inside the box. The bottom and top of the box represent the 25th and 75th percentiles. The vertical line extends to the minimum and maximum data values.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3140268&req=5

f1-bcbcr-5-2011-155: Comparison of the GP88 level in healthy volunteers (HV) and breast cancer patients separated by stages (Stage 1–3) and stage 4. GP88 serum levels in healthy volunteers and breast cancer patients stage 1–3 and stage 4 were represented by box and whisker plots. The mean is represented by a + sign. The median is represented by the line inside the box. The bottom and top of the box represent the 25th and 75th percentiles. The vertical line extends to the minimum and maximum data values.
Mentions: Statistical analysis of the results in Table 2 indicated that serum GP88 values were significantly elevated in both early stage (P = 0.007) and stage 4 patients (P = 0.0007) when compared to the GP88 serum level of healthy subjects. In addition, as shown in Figure 1, the range of GP88 values was much larger in BC patients than in healthy individuals reaching 100 ng/ml for stage 1–3 patients and 158 ng/ml in stage 4 patients when compared HV where the highest values was 39 ng/ml.

Bottom Line: Serum GP88 level was 28.7 + 5.8 ng/ml in HV and increased to 40.7 + 16.0 ng/ml (P = 0.007) for stage 1-3 and 45.3 + 23.3 ng/ml (P = 0.0007) for stage 4 BC patients.There was no correlation between the GP88 level and BC characteristics such as age, race, tumor grade, ER, PR and HER-2 expression.These data suggest that serial testing of serum GP88 levels may have value as a circulating biomarker for detection, monitoring and follow up of BC.

View Article: PubMed Central - PubMed

Affiliation: University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD, USA.

ABSTRACT

Introduction: GP88 (PC-Cell Derived Growth Factor, progranulin) is a glycoprotein overexpressed in breast tumors and involved in their proliferation and survival. Since GP88 is secreted, an exploratory study was established to compare serum GP88 level between breast cancer patients (BC) and healthy volunteers (HV).

Methods: An IRB approved prospective study enrolled 189 stage 1-4 BC patients and 18 HV. GP88 serum concentration was determined by immunoassay.

Results: Serum GP88 level was 28.7 + 5.8 ng/ml in HV and increased to 40.7 + 16.0 ng/ml (P = 0.007) for stage 1-3 and 45.3 + 23.3 ng/ml (P = 0.0007) for stage 4 BC patients. There was no correlation between the GP88 level and BC characteristics such as age, race, tumor grade, ER, PR and HER-2 expression.

Conclusion: These data suggest that serial testing of serum GP88 levels may have value as a circulating biomarker for detection, monitoring and follow up of BC.

No MeSH data available.


Related in: MedlinePlus